Hyphens Pharma International's (SGX:1J5) subsidiary, Hyphens Pharma, expanded its partnership with German pharmaceutical firm, Medac Gesellschaft, to bring its Metoject subcutaneous autoinjector pen to Thailand and Cambodia.
The extension is part of an existing agreement that allows Hyphens to have exclusive rights to register and market the Meteoject subcutaneous autoinjector pen, according to a Thursday filing with the Singapore Exchange.
The pen is approved and available in 15 countries and is considered a first-line treatment for rheumatoid arthritis.
Shares of the company were down nearly 2% at the close of trading on Thursday.